The glucocorticoid receptor (GR) is a ligand-activated transcription factor that mediates virtually all known genomic actions of glucocorticoids (GCs). Understanding GR biology at the molecular level explains both the therapeutic breadth of corticosteroid therapy and its extensive side effect profile: GR is expressed in essentially every nucleated cell in the body, and its transcriptional targets span metabolism, immunity, bone, growth, and neuroendocrine regulation. The predominant functionally active isoform, GR-alpha (GR-α), is the pharmacological target of all clinically used corticosteroids.
GR-α Domain Architecture. The glucocorticoid receptor alpha (GR-α) is encoded by the NR3C1 (nuclear receptor subfamily 3, group C, member 1) gene on chromosome 5 and is organized into three functional domains. The N-terminal transactivation domain (NTD, also called AF-1) interacts with coregulator proteins and contains the activation function-1 site. The central DNA (deoxyribonucleic acid)-binding domain (DBD) contains two zinc finger motifs that recognize specific glucocorticoid response element (GRE) half-site sequences and mediate receptor dimerization on DNA. The C-terminal ligand-binding domain (LBD) houses the hormone-binding pocket, a heat shock protein (HSP) interaction surface, and the activation function-2 (AF-2) site that recruits coactivators upon ligand binding. In the unliganded cytoplasmic state, GR-α is maintained in an inactive complex with heat shock protein 90 (HSP90), heat shock protein 70 (HSP70), and p23 (a co-chaperone) as well as immunophilins (FKBP51, FKBP52), which collectively stabilize the receptor in a high-affinity ligand-binding conformation while sequestering it from the nucleus and preventing inadvertent transcription.1
Ligand Binding and Nuclear Translocation. Glucocorticoids are lipophilic molecules that freely cross the plasma membrane and bind to GR-α in the cytoplasm, inducing a conformational change in the LBD that disrupts the heat shock protein complex and exposes a nuclear localization signal (NLS) on the DBD. The glucocorticoid-GR (GC-GR) complex is then actively imported into the nucleus via importin-alpha and importin-beta nuclear transport proteins. The entire process of ligand binding to nuclear entry occurs within minutes, making the GR activation pathway rapid relative to the time scale of transcriptional responses, which unfold over hours. Once in the nucleus, the activated GR has several mechanisms of action, each producing distinct functional outputs: direct DNA binding at GREs, tethering to other transcription factors without DNA binding, and non-genomic signaling at the membrane and cytoplasm.1
Transactivation at GREs. The classical mechanism of GR action involves GR homodimerization on the DBD, followed by binding to palindromic glucocorticoid response element (GRE) sequences in the promoter or enhancer regions of target genes. GRE-bound GR recruits transcriptional coactivator complexes, including steroid receptor coactivator (SRC) family proteins, including SRC-1 (SRC-1), SRC-2 (glucocorticoid receptor-interacting protein-1, GRIP-1), and SRC-3 (amplified in breast cancer 1, AIB1), which in turn recruit the p300/CBP (CREB-binding protein) acetyltransferases that acetylate histones and remodel chromatin into a transcriptionally active configuration. GRE-driven transactivation upregulates genes whose protein products mediate many of the metabolic consequences of glucocorticoid (GC) excess: gluconeogenic enzymes (phosphoenolpyruvate carboxykinase, glucose-6-phosphatase), genes involved in lipolysis, and anti-inflammatory genes such as annexin A1 (lipocortin-1), MAPK (mitogen-activated protein kinase) phosphatase-1 (MKP-1), and the glucocorticoid-inducible leucine zipper protein (GILZ). Some GRE-driven transactivation targets also produce anti-inflammatory effects, challenging the older conceptual framework that transactivation was solely responsible for metabolic toxicity while transrepression was solely responsible for anti-inflammatory benefit.12
Transrepression of Inflammatory Transcription Factors. Transrepression is the mechanism by which GR (glucocorticoid receptor) suppresses the activity of pro-inflammatory transcription factors without directly binding DNA. The two most important transrepression targets are nuclear factor kappa B (NF-κB) and AP-1 (activator protein-1, a heterodimer of Fos and Jun family proteins). Monomeric GR directly interacts with the p65 (RelA) subunit of NF-κB through protein-protein tethering, preventing NF-κB from binding to its cognate response elements in the promoters of pro-inflammatory cytokine genes (interleukin-1 (IL-1), interleukin-2 (IL-2), interleukin-6 (IL-6), interleukin-8 (IL-8), tumor necrosis factor-alpha (TNF-α)). GR similarly tethers to and inhibits AP-1, suppressing AP-1-driven transcription of matrix metalloproteinases and additional cytokine genes. Transrepression also involves GR-mediated recruitment of histone deacetylase 2 (HDAC2) to NF-κB-responsive promoters, reversing the histone acetylation that maintains chromatin in a pro-inflammatory open state. In COPD (chronic obstructive pulmonary disease), oxidative stress impairs HDAC2 activity, reducing corticosteroid responsiveness through this mechanism, which is one explanation for the relative steroid resistance observed in COPD airways compared to asthma.23
GR Isoform Diversity and Non-Genomic Signaling. Alternative splicing of the NR3C1 pre-mRNA generates at least eight GR isoforms; GR-beta (GR-β) is the most clinically relevant alternative, differing from GR-α only in the C-terminal LBD where a distinct 15-amino-acid sequence replaces the last 50 amino acids of GR-α. GR-β cannot bind glucocorticoids, does not activate GRE-driven transcription, and acts as a dominant negative inhibitor of GR-α by competing for GRE binding sites and coactivator proteins. Elevated GR-β to GR-α ratios have been identified in glucocorticoid-resistant asthma, steroid-resistant nephrotic syndrome, and rheumatoid arthritis, providing a molecular basis for clinical steroid resistance in some patients. Non-genomic GR signaling occurs within seconds to minutes, too rapid for transcriptional mechanisms, and involves membrane-associated GR, cytoplasmic GR interactions with signaling kinases (Src, PI3K, MAPK), and displacement of signaling proteins from the HSP90 complex upon ligand binding; these rapid effects contribute to the acute anti-inflammatory and vascular actions of high-dose intravenous corticosteroids.1
GC binds cytoplasmic GR-α → HSP90/HSP70/p23 complex dissociates → NLS exposed → importin-mediated nuclear entry (minutes) → GR homodimerizes and binds GREs (transactivation) or tethers to NF-κB/AP-1 (transrepression) → transcriptional changes over hours. Anti-inflammatory transrepression suppresses IL-1, IL-2, IL-6, IL-8, TNF-α, and matrix metalloproteinase gene expression. Metabolic transactivation upregulates gluconeogenic enzymes, lipocortin-1, MKP-1, and GILZ. HDAC2 recruitment to pro-inflammatory promoters is the mechanism by which GR reverses histone acetylation at cytokine gene loci.
Corticosteroids suppress inflammation through a coordinated set of mechanisms that collectively target every major arm of the inflammatory response: arachidonic acid (AA) generation, cytokine production, leukocyte recruitment and survival, vascular permeability, and fibroblast activity. The breadth of this suppression is both the source of corticosteroids' unrivaled anti-inflammatory potency and the reason their side effects are so wide-ranging when used chronically at supraphysiological doses.
Lipocortin-1 (Annexin A1) and Phospholipase A2 Inhibition. One of the earliest and most mechanistically important anti-inflammatory effects of corticosteroids is the glucocorticoid response element (GRE)-driven induction of annexin A1 (lipocortin-1), a calcium-dependent phospholipid-binding protein that inhibits cytosolic phospholipase A2 (PLA2). PLA2 catalyzes the rate-limiting step in eicosanoid biosynthesis: the liberation of arachidonic acid (AA) from membrane phospholipids. By inducing lipocortin-1, corticosteroids suppress AA release, reducing substrate availability for both the COX (cyclooxygenase) and 5-LOX (lipoxygenase) pathways simultaneously. This is the key pharmacological distinction from NSAIDs (non-steroidal anti-inflammatory drugs): NSAIDs act downstream of PLA2 and block only the COX pathway, leaving the LOX pathway intact; corticosteroids act upstream of the branch point and suppress both. The clinical consequence is that corticosteroids have a broader eicosanoid-suppressive effect than NSAIDs and are effective in aspirin-exacerbated respiratory disease (AERD), where unopposed LOX activity following COX inhibition underlies the bronchoconstriction.34
Inducible Enzyme Suppression. Independently of lipocortin-1, the glucocorticoid receptor (GR) transrepression of nuclear factor kappa B (NF-κB) and activator protein-1 (AP-1) suppresses the transcription of inducible cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS). COX-2 is the inducible prostaglandin-synthesizing enzyme upregulated during inflammation by cytokines and LPS (lipopolysaccharide); its suppression by corticosteroids reduces inflammatory prostaglandin generation via a second, post-transcriptional mechanism in addition to the PLA2/lipocortin pathway. The suppression of iNOS reduces nitric oxide production in activated macrophages and endothelial cells, attenuating vasodilation, vascular permeability, and macrophage cytotoxic activity. This dual mechanism of arachidonic acid pathway suppression (upstream PLA2 inhibition plus downstream COX-2 gene suppression) makes corticosteroids more potent anti-inflammatory agents than any NSAID (non-steroidal anti-inflammatory drug) at equi-effective doses.24
Cytokine Gene Transrepression. Through transrepression of NF-κB and AP-1, corticosteroids broadly suppress the production of pro-inflammatory cytokines and chemokines. The principal targets include interleukin-1β (IL-1β), interleukin-2 (IL-2), interleukin-3 (IL-3), interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-6 (IL-6), interleukin-8 (IL-8, also CXCL8), interleukin-12 (IL-12), interleukin-13 (IL-13), tumor necrosis factor-alpha (TNF-α), granulocyte-macrophage colony-stimulating factor (GM-CSF), and RANTES (CCL5). Of these, the suppression of IL-5 and GM-CSF is particularly important in eosinophilic inflammation because these cytokines are the principal survival factors for eosinophils; their withdrawal triggers eosinophil apoptosis. The suppression of IL-2 and IL-12 reduces T helper cell activation and proliferation, contributing to the immunosuppressive effects used in autoimmune disease and transplantation. Corticosteroids also upregulate the anti-inflammatory cytokine interleukin-10 (IL-10) and the inhibitory I-κBα protein that sequesters NF-κB in the cytoplasm, creating positive feedback loops that amplify and maintain the anti-inflammatory state.2
Effects on Leukocyte Trafficking and Survival. Corticosteroids profoundly alter leukocyte trafficking and survival in ways that collectively reduce inflammatory infiltration of target tissues. Neutrophils are the most numerically affected cell type: a single dose of corticosteroid causes neutrophilia within 4 to 6 hours through two mechanisms, demargination of neutrophils from vascular endothelium (reduced adhesion molecule expression, including ICAM-1 and E-selectin) and release from the bone marrow storage pool. Despite the increase in circulating neutrophil numbers, corticosteroids reduce neutrophil influx into inflamed tissues by suppressing chemokine production and downregulating neutrophil surface adhesion receptors. Eosinophils are exquisitely sensitive to corticosteroids: blood eosinophilia is effectively suppressed through promotion of eosinophil apoptosis, reduced bone marrow eosinophil release, and tissue eosinophil redistribution. Lymphopenia occurs through redistribution of circulating T and B lymphocytes to lymphoid organs rather than through direct cytotoxicity at standard doses; however, high-dose or prolonged corticosteroid therapy causes true lymphocyte apoptosis, particularly of CD4⁺ (cluster of differentiation 4-positive) T cells. Monocytes and macrophages are reduced in the blood and display impaired phagocytosis, antigen presentation, and cytokine production, accounting for corticosteroids' ability to suppress both innate and adaptive immunity.45
Effects on Vascular Permeability and Tissue Remodeling. Corticosteroids reduce vascular permeability by upregulating lipocortin-1, suppressing histamine release from mast cells (through reduced IgE-receptor signaling and cytokine production), and downregulating the expression of vascular endothelial growth factor (VEGF) in inflamed tissues. The net effect is attenuation of the local edema that characterizes acute inflammation. In chronic inflammation, corticosteroids suppress fibroblast proliferation and reduce collagen synthesis through downregulation of TGF-beta (transforming growth factor beta) pathways; paradoxically, this same anti-fibrotic effect underlies the skin thinning, impaired wound healing, and susceptibility to skin tears that are adverse effects of systemic corticosteroid therapy. Suppression of osteoblast activity and promotion of bone resorption through RANKL (receptor activator of NF-κB ligand) upregulation and OPG (osteoprotegerin) downregulation form the basis of glucocorticoid-induced osteoporosis, the most clinically important long-term skeletal consequence of corticosteroid use.6
NSAIDs: block COX only; leave LOX pathway active; do not suppress cytokine transcription; do not affect leukocyte trafficking; no immunosuppressive effect. Corticosteroids: suppress PLA2 (upstream of COX and LOX) via lipocortin-1; suppress COX-2 gene transcription; suppress LOX-derived leukotrienes; transrepress NF-κB and AP-1 → suppress cytokine production; promote eosinophil apoptosis; redistribute lymphocytes; reduce vascular permeability. Corticosteroids therefore have broader and more potent anti-inflammatory activity at the cost of broader side effects, including immunosuppression, metabolic effects, and HPA axis suppression, which NSAIDs do not produce.
The pharmacokinetic properties of individual corticosteroids determine their clinical roles, dosing intervals, and interactions. Key features that vary across agents include oral bioavailability, whether the drug is a prodrug requiring hepatic activation, CYP3A4 (cytochrome P450 3A4) dependency, plasma protein binding, and half-life. The comparative potency table, anchored to hydrocortisone as the reference compound, is essential clinical knowledge for dose conversions and for understanding the mineralocorticoid side effects that differ substantially across agents.
Absorption and Oral Bioavailability. Most oral corticosteroids are well absorbed from the gastrointestinal (GI) tract with bioavailability ranging from 70% for prednisolone to greater than 80% for methylprednisolone and dexamethasone. Prednisone is the most widely prescribed oral corticosteroid in clinical medicine. It is pharmacologically inactive as administered and requires hepatic 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-HSD1) to convert the 11-keto group to an 11-beta-hydroxyl, generating the active metabolite prednisolone. In patients with severe hepatic disease, this conversion may be impaired, and prednisolone itself is preferred because it does not require this activation step. The oral-to-intravenous (IV) conversion is approximately 1:1 for methylprednisolone and prednisolone, simplifying transitions between routes. Topical and inhaled corticosteroids are subject to first-pass hepatic metabolism that substantially reduces systemic bioavailability, which is the pharmacokinetic basis for their therapeutic window advantage over systemic formulations.6
CYP3A4 Metabolism and Drug Interactions. Corticosteroids are substrates for cytochrome P450 3A4 (CYP3A4) in the liver and intestinal wall. CYP3A4 inhibitors raise corticosteroid plasma levels, increasing efficacy and toxicity; common examples include azole antifungals (ketoconazole, itraconazole, voriconazole), macrolide antibiotics (clarithromycin, erythromycin), HIV (human immunodeficiency virus) protease inhibitors (ritonavir), and diltiazem. CYP3A4 inducers accelerate corticosteroid clearance, potentially causing therapeutic failure; rifampin is the most potent inducer encountered clinically and can reduce plasma corticosteroid levels by 50 to 75%, sometimes precipitating adrenal insufficiency in patients dependent on exogenous steroids. Ritonavir deserves special attention: it powerfully inhibits CYP3A4 and has been documented to cause iatrogenic Cushing syndrome and secondary adrenal insufficiency when co-administered with inhaled fluticasone or injected triamcinolone, even at non-systemic doses. This interaction is important in patients with HIV on ritonavir-containing antiretroviral regimens who receive inhaled or injected corticosteroids for asthma or musculoskeletal indications.6
Plasma Protein Binding and Half-Life. Corticosteroids circulate in plasma bound to two proteins: CBG (corticosteroid-binding globulin, also called transcortin) and albumin. At physiological concentrations, approximately 75 to 80% of cortisol is bound to CBG and 15% to albumin, with only 5 to 10% free (pharmacologically active). At pharmacological doses, CBG binding saturates and a larger free fraction circulates; this non-linear relationship means that modest dose increases at higher dose levels produce disproportionately large increases in free drug. Synthetic corticosteroids such as dexamethasone and methylprednisolone bind CBG with low affinity and are primarily albumin-bound, resulting in a relatively larger free fraction at all doses compared to cortisol and prednisolone. Plasma half-life reflects plasma clearance only and does not correspond to biological duration of action, which is determined by the duration of GR (glucocorticoid receptor)-driven transcriptional changes. Cortisol and prednisone have plasma half-lives of approximately 60 to 90 minutes and 60 minutes respectively, yet their biological half-lives are 8 to 12 hours, permitting once or twice daily dosing. Dexamethasone has a plasma half-life of approximately 4 hours and a biological half-life of 36 to 54 hours, making it suitable for single-dose anti-emetic use and for situations where prolonged HPA (hypothalamic-pituitary-adrenal) axis suppression is required (e.g., dexamethasone suppression tests).6
Comparative Potency. Corticosteroid potency is conventionally expressed relative to hydrocortisone (cortisol), which is assigned a glucocorticoid potency of 1 and a mineralocorticoid potency of 1. Mineralocorticoid activity is clinically important because activation of the mineralocorticoid receptor (MR) in the renal collecting duct promotes sodium retention and potassium excretion, causing hypertension, hypokalemia, and edema. Fludrocortisone is a synthetic corticosteroid used therapeutically for its potent mineralocorticoid activity in conditions such as primary adrenal insufficiency and orthostatic hypotension. Understanding the glucocorticoid-to-mineralocorticoid ratio of each agent determines which drug is preferred in different clinical settings and predicts which adverse metabolic effects are most likely. The anti-inflammatory (glucocorticoid) equipotency information is used to perform dose conversions when switching between agents: for example, 5 mg of prednisone is approximately equivalent to 4 mg of methylprednisolone and 0.75 mg of dexamethasone in anti-inflammatory potency.7
| Agent | GC Potency (vs HC) | MC Potency (vs HC) | Plasma t½ | Biological t½ | Equivalent Anti-Inflammatory Dose |
|---|---|---|---|---|---|
| Hydrocortisone (cortisol) | 1 | 1 | 60–90 min | 8–12 h | 20 mg |
| Prednisone (prodrug → prednisolone) | 4 | 0.8 | ~60 min | 12–36 h | 5 mg |
| Prednisolone | 4 | 0.8 | 2–3.5 h | 12–36 h | 5 mg |
| Methylprednisolone | 5 | 0.5 | 2.5–3.5 h | 12–36 h | 4 mg |
| Triamcinolone | 5 | 0 | 2–5 h | 12–36 h | 4 mg |
| Dexamethasone | 25–30 | 0 | 3–4.5 h | 36–54 h | 0.75 mg |
| Betamethasone | 25–30 | 0 | 3–5 h | 36–54 h | 0.75 mg |
| Fludrocortisone | 10–15 | 125–150 | 3.5 h | 12–36 h | — |
Hydrocortisone 20 mg = Prednisone/prednisolone 5 mg = Methylprednisolone/triamcinolone 4 mg = Dexamethasone/betamethasone 0.75 mg. Fludrocortisone is used exclusively for mineralocorticoid replacement and does not have a meaningful anti-inflammatory equivalent dose in routine practice. Dexamethasone and betamethasone have negligible mineralocorticoid activity, making them preferred when sodium retention is undesirable (cerebral edema, fetal lung maturation, congenital adrenal hyperplasia suppression). Prednisone is the standard oral agent for most chronic indications; methylprednisolone sodium succinate is preferred IV for acute severe situations (asthma, spinal cord injury, MS relapse) due to its rapid onset and minimal mineralocorticoid effect.
Systemic corticosteroids have the broadest clinical application of any drug class in medicine. They span emergency interventions where minutes matter (anaphylaxis, acute severe asthma, spinal cord injury), organ-threatening autoimmune diseases (SLE (systemic lupus erythematosus) nephritis, ANCA (anti-neutrophil cytoplasmic antibody)-associated vasculitis, myasthenic crisis), transplant immunosuppression, and lifelong physiological hormone replacement in adrenal insufficiency. Selecting the right agent, dose, and route for the indication is as important as the decision to treat.
Emergency and Acute Applications. Anaphylaxis: hydrocortisone 200 mg IV or methylprednisolone 1 to 2 mg/kg IV is administered as adjunctive therapy after epinephrine; the principal rationale is prevention of the biphasic anaphylactic reaction occurring 4 to 12 hours after the initial event, although the evidence for this benefit is less robust than the evidence for epinephrine. Acute severe asthma: systemic corticosteroids administered within one hour of emergency presentation reduce hospital admission rates and treatment failure; methylprednisolone 40 to 80 mg IV or prednisolone 40 to 50 mg orally are equivalent and both evidence-based. Spinal cord injury: high-dose methylprednisolone (30 mg/kg IV bolus over 15 minutes, then 5.4 mg/kg/hour for 23 hours) was widely used for decades based on NASCIS (National Acute Spinal Cord Injury Study) trial data; current evidence no longer supports this protocol as standard of care due to significant harm (infection, GI (gastrointestinal) bleeding, pulmonary embolism) with uncertain benefit, and most guidelines no longer recommend it. Cerebral edema: dexamethasone 4 mg every 6 hours IV is the standard for vasogenic edema associated with brain tumors and metastases; it is ineffective and potentially harmful in cytotoxic edema from ischemic stroke.7
Inflammatory and Autoimmune Indications. Systemic lupus erythematosus (SLE) with nephritis or severe organ involvement: high-dose prednisone (0.5 to 1.0 mg/kg/day) combined with immunosuppressive therapy (cyclophosphamide or mycophenolate) is the standard induction regimen. ANCA-associated vasculitis (granulomatosis with polyangiitis, microscopic polyangiitis): high-dose pulse methylprednisolone (500 to 1,000 mg IV daily for 3 days) followed by oral prednisone for induction. Polymyalgia rheumatica (PMR): low-dose prednisone (12.5 to 25 mg/day) produces dramatic symptomatic relief within days; PMR is one of the few conditions in which corticosteroids alone are considered diagnostic as well as therapeutic. Giant cell arteritis (GCA): high-dose prednisone (40 to 60 mg/day) is initiated immediately when GCA is suspected to prevent ischemic vision loss from ophthalmic artery involvement; treatment should not wait for temporal artery biopsy results. Autoimmune hemolytic anemia and immune thrombocytopenic purpura (ITP): prednisone 1 mg/kg/day. Myasthenic crisis: high-dose IV methylprednisolone; note that in non-crisis myasthenia gravis, corticosteroids can transiently worsen weakness (cholinergic mechanism) before improving it, so initiation is typically inpatient.9
Transplantation and Oncology. Corticosteroids remain a core component of most solid organ transplant immunosuppression protocols, typically as triple therapy (calcineurin inhibitor + antimetabolite + corticosteroid). In acute cellular rejection, pulse methylprednisolone (500 to 1,000 mg IV daily for 3 days) is the first-line treatment. In bone marrow transplantation, corticosteroids are first-line therapy for acute graft-versus-host disease (GVHD) affecting the skin, GI tract, or liver. In oncology, dexamethasone serves multiple roles: as an anti-emetic for chemotherapy-induced nausea (8 to 20 mg IV before chemotherapy), as a component of lymphoma treatment regimens (e.g., R-CHOP), for hypercalcemia of malignancy, and for reducing cerebral edema from brain metastases.8
Adrenal Insufficiency Replacement. Primary adrenal insufficiency (Addison disease) requires both glucocorticoid and mineralocorticoid replacement. Hydrocortisone 15 to 25 mg/day in divided doses (typically two-thirds in the morning, one-third in the early afternoon) mimics the diurnal cortisol rhythm and is the preferred GC (glucocorticoid) for replacement. Fludrocortisone 0.05 to 0.2 mg/day provides mineralocorticoid replacement. Secondary adrenal insufficiency (ACTH deficiency) requires GC replacement only, as aldosterone production through the renin-angiotensin pathway is preserved. In both forms, sick day rules (doubling or tripling the oral corticosteroid dose during febrile illness) and emergency hydrocortisone injection (100 mg IM) for vomiting or surgical stress are mandatory patient education components. Congenital adrenal hyperplasia (CAH) requires a slightly supraphysiological GC dose (to suppress ACTH-driven androgen excess) combined with fludrocortisone; dexamethasone is used for prenatal CAH treatment (to suppress fetal adrenal androgen production before genotyping results are available) and for suppression therapy in adults with classic CAH.7
Giant cell arteritis can cause permanent, bilateral vision loss from anterior ischemic optic neuropathy due to inflammation of the ophthalmic and posterior ciliary arteries. When the clinical presentation is consistent with GCA (age above 50, jaw claudication, new headache, tender temporal artery, elevated ESR/CRP), high-dose prednisone (40 to 60 mg/day) should be initiated immediately. Temporal artery biopsy remains the gold standard for diagnosis and should be performed within 1 to 2 weeks of starting corticosteroids, as the histologic findings (granulomatous arteritis with giant cells) persist for at least 2 weeks after steroid initiation. Delaying treatment pending biopsy results risks irreversible vision loss.
Inhaled corticosteroids (ICS) represent one of the most successful applications of targeted drug delivery in clinical pharmacology: by depositing high concentrations of corticosteroid directly onto inflamed airway mucosa while exploiting extensive first-pass hepatic metabolism to minimize systemic exposure, ICS achieve local anti-inflammatory efficacy comparable to moderate-dose systemic therapy with a markedly more favorable systemic side effect profile. They are the cornerstone of chronic asthma management and have an evidence-based, though more limited, role in COPD (chronic obstructive pulmonary disease).
Pharmacokinetic Basis of the ICS Therapeutic Advantage. The favorable therapeutic window of ICS depends on two pharmacokinetic features: efficient pulmonary deposition with high local airway concentrations, and rapid systemic clearance of any absorbed drug through first-pass hepatic metabolism. After inhalation, approximately 10 to 40% of the delivered dose reaches the lower airways (lung deposition fraction), depending on the device type, particle size, and inhalation technique; the remainder deposits in the oropharynx, is swallowed, and enters the GI (gastrointestinal) tract. The systemically absorbed fraction (from both pulmonary and GI absorption) reaches the hepatic portal circulation, where first-pass metabolism by CYP3A4 (cytochrome P450 3A4) rapidly inactivates most ICS. Fluticasone propionate and fluticasone furoate have essentially zero oral bioavailability due to near-complete first-pass extraction, meaning that the swallowed oropharyngeal fraction contributes minimally to systemic exposure. Budesonide undergoes extensive hepatic first-pass metabolism (approximately 90%), and ciclesonide is a prodrug that is activated by esterases in the lung to the active form des-ciclesonide, with the remaining prodrug inactivated hepatically before reaching systemic circulation. In contrast, older agents such as beclomethasone dipropionate have lower first-pass extraction and higher systemic bioavailability, explaining the higher systemic side effect rates seen historically with high-dose beclomethasone compared to fluticasone at equivalent anti-asthmatic doses.10
Comparative ICS Agents. The major ICS in clinical use differ in potency, lipophilicity, receptor binding affinity, and pharmacokinetic profile. Fluticasone propionate has one of the highest GR (glucocorticoid receptor) binding affinities of any ICS and a long GR occupancy time, contributing to its potency; it is available in metered-dose inhalers (MDI) and dry powder inhalers (DPI). Budesonide (nebulization solution, DPI, and as a combination product with formoterol) is notable for forming fatty acid esters within lung cells that serve as an intrapulmonary depot, prolonging local drug retention. Mometasone furoate and fluticasone furoate are newer high-potency ICS with once-daily dosing options. Beclomethasone dipropionate (BDP) is a prodrug converted to beclomethasone-17-monopropionate (17-BMP) in the lung; with small-particle formulations (<2 micrometers), BDP can deposit in small airways and peripheral lung regions that larger particles cannot reach, a potential advantage in small-airway asthma. Ciclesonide, a prodrug activated in the lung, has very high oropharyngeal deposition safety because the prodrug is not pharmacologically active at the oropharyngeal mucosa.10
ICS in Asthma Management. ICS are the foundation of step-up asthma therapy in international GINA (Global Initiative for Asthma) guidelines. At Step 2, low-dose ICS monotherapy is recommended for persistent asthma; at Step 3, the preferred option is low-dose ICS combined with a long-acting beta-2 agonist (LABA), which is more effective than doubling the ICS dose alone. The ICS (inhaled corticosteroid)-LABA (long-acting beta-2 agonist) combination achieves greater asthma control by exploiting pharmacological synergy: LABAs increase GR nuclear translocation and GC (glucocorticoid) responsiveness, while ICS prevent LABA-induced beta-2 receptor downregulation. Evidence that LABA monotherapy without ICS increases asthma mortality (the SMART trial) establishes the principle that LABA should never be used in asthma without concomitant ICS. At higher steps, medium- or high-dose ICS-LABA (ICS plus LABA combination), with or without tiotropium or anti-IgE (omalizumab) or anti-IL-5 (mepolizumab, reslizumab) biologic therapies, is recommended. Oral thrush (oropharyngeal candidiasis) from residual ICS deposition in the oropharynx is reduced by spacer use, rinsing the mouth after inhalation, and by switching to prodrug ICS (ciclesonide).11
ICS in COPD. The role of ICS in COPD is more restricted than in asthma and has evolved considerably over the past decade. ICS alone do not reduce COPD mortality and are not recommended as monotherapy for COPD. Triple inhaled therapy (ICS + LABA + LAMA (long-acting muscarinic antagonist)) reduces COPD exacerbation rates and mortality compared to dual bronchodilator therapy in patients with frequent exacerbations (≥2 per year or one hospitalization) and blood eosinophil counts above 300 cells per microliter, a biomarker that predicts ICS responsiveness. The WISDOM (Withdrawal of Inhaled Steroids during Optimised bronchodilator Management) trial confirmed that ICS can be withdrawn from stable COPD patients without increasing exacerbations when dual bronchodilator therapy is continued, but only in patients with low blood eosinophil counts. The risk of pneumonia is specifically elevated with ICS use in COPD and is not offset by exacerbation reduction in patients with low eosinophil counts (<100 per microliter), making blood eosinophil count a practical guide to ICS use in COPD. Fluticasone-containing combinations carry a higher pneumonia risk in COPD than budesonide-containing combinations in some analyses, though both increase absolute pneumonia risk relative to bronchodilator therapy alone.11
Oropharyngeal candidiasis: caused by residual ICS deposition in the oropharynx; prevent with spacer device (MDI), rinsing mouth and gargling after each dose, and using prodrug ICS (ciclesonide). Dysphonia (hoarseness): local corticosteroid effect on laryngeal muscles; spacer reduces deposition; may require dose reduction. Reflex cough: more common with MDI than DPI; switching device may help. All systemic side effects of inhaled steroids (growth suppression in children, HPA axis suppression, osteoporosis, skin thinning, cataracts) are dose-dependent, more common at high doses, and substantially less frequent than with equivalent anti-inflammatory doses of systemic corticosteroids.
Hypothalamic-pituitary-adrenal (HPA) axis suppression is an inevitable consequence of supraphysiological corticosteroid exposure sustained beyond approximately 2 to 3 weeks, and it represents the single most common and potentially most dangerous adverse effect of systemic corticosteroid therapy. Understanding the mechanisms, the predictors of suppression severity, and the principles of stress dosing and tapering is mandatory knowledge for any clinician who prescribes these drugs.
Mechanism of HPA Axis Suppression. The hypothalamus secretes corticotropin-releasing hormone (CRH) in a pulsatile, diurnal pattern that peaks in the early morning, driving pituitary corticotroph cells to release adrenocorticotropic hormone (ACTH), which in turn stimulates the adrenal cortex to produce cortisol. Exogenous glucocorticoids suppress this axis through negative feedback at both the hypothalamic (CRH suppression) and pituitary (ACTH suppression) levels. At pharmacological doses, GR (glucocorticoid receptor) activation in the hypothalamus and anterior pituitary reduces CRH and ACTH gene transcription, blunts the normal morning cortisol surge, and reduces adrenal cortical sensitivity to ACTH through downregulation of adrenal ACTH receptors (MC2R). With prolonged supraphysiological exposure, ACTH levels fall chronically, the adrenal cortex undergoes atrophy, and endogenous cortisol production capacity diminishes proportionately. The result is a state of secondary adrenal insufficiency that manifests clinically when exogenous corticosteroids are withdrawn faster than the hypothalamic-pituitary-adrenal axis can recover its endogenous production capacity.12
Predictors of HPA Axis Suppression. The likelihood and severity of HPA axis suppression depend on dose, duration, timing, and the potency of the corticosteroid used. Any patient who has received more than 20 mg/day of prednisone (or the equivalent) for more than 3 weeks is likely to have some degree of HPA suppression. Lower doses may also cause suppression with very prolonged use. Administration in the morning, which mimics the natural cortisol peak, causes less HPA suppression than equivalent doses given in the evening or as split doses throughout the day, because exogenous morning dosing overlaps with the natural peak and less effectively suppresses the trough that normally triggers CRH and ACTH release. Alternate-day prednisone therapy, in which the total dose is given as a double dose every 48 hours rather than daily, reduces HPA suppression more effectively than any other dosing modification while preserving anti-inflammatory efficacy in many (though not all) indications. Dexamethasone's long biological half-life (36 to 54 hours) makes it particularly prone to HPA suppression at even modest doses and is the reason it is not preferred for long-term anti-inflammatory use despite its high potency.1213
Clinical Manifestations of Secondary Adrenal Insufficiency. Secondary adrenal insufficiency (SAI) from exogenous corticosteroid withdrawal differs from primary adrenal insufficiency (Addison disease) in two important respects: mineralocorticoid production is preserved (because aldosterone is regulated by the renin-angiotensin-aldosterone system, not ACTH), and hyperpigmentation does not occur (because ACTH is low rather than high). SAI presents with fatigue, nausea, anorexia, arthralgia, myalgia, hypotension, and hypoglycemia; salt craving and hyperkalemia are absent because aldosterone production is intact. The most dangerous manifestation is an adrenal crisis precipitated by physiological stress (surgery, severe infection, trauma) in a patient whose adrenal axis has not recovered sufficiently to mount the normal 3- to 5-fold increase in cortisol output required to survive significant physiological stress. Patients with any degree of HPA suppression should carry a steroid emergency card and a prefilled hydrocortisone injection kit (100 mg IM hydrocortisone) and be instructed in sick day rules and circumstances requiring emergency injection.12
Stress Dosing Protocols. Stress dosing refers to the administration of supplemental corticosteroid during physiological stress in patients with actual or presumed HPA axis suppression. The physiological basis is that the adrenal gland normally increases cortisol output from a basal rate of approximately 8 to 10 mg of cortisol per day to 75 to 150 mg per day during major surgery or critical illness. Patients with HPA suppression cannot generate this increase endogenously. The traditional approach has been to administer hydrocortisone 100 mg IV every 8 hours during major surgery, tapering over 1 to 3 days postoperatively. More recent evidence supports a nuanced approach based on the degree of suppression: minor surgery (hernia repair, dental extraction) and minor illness (febrile infection without vomiting) may require only doubling or tripling the usual oral dose; major surgery or ICU admission requires full stress coverage (hydrocortisone 50 to 100 mg IV every 6 to 8 hours). Patients who cannot take oral medications due to vomiting or surgery require parenteral hydrocortisone administration regardless of the procedure magnitude.13
Tapering Principles. The pace of corticosteroid tapering must balance two risks: relapse of the underlying inflammatory or autoimmune condition if tapered too rapidly, and prolonged HPA suppression if the dose is maintained too long at supraphysiological levels. For short courses (<3 weeks) at any dose, abrupt discontinuation is generally safe without a formal taper because HPA suppression is unlikely. For courses longer than 3 weeks, tapering is required. A common approach for moderate-dose courses (20 to 40 mg/day prednisone for 4 to 8 weeks) is to reduce by 5 to 10 mg per week until the physiological replacement range is reached (5 to 7.5 mg/day), then reduce by 1 mg per week (or 1 mg every 2 weeks). The physiological range is typically the final 4 to 8 weeks of tapering, during which the HPA axis is recalibrating its own cortisol output to fill the gap left by the diminishing exogenous steroid. Monitoring for symptoms of adrenal insufficiency (fatigue, nausea, hypotension) during the taper guides the pace; morning serum cortisol levels below 3 micrograms per deciliter (83 nmol/L) or a subnormal cortisol response on ACTH stimulation testing indicate incomplete HPA recovery and support temporary dose increase.13
Any corticosteroid course exceeding 20 mg/day prednisone for more than 3 weeks: counsel patient on sick day rules, provide written guidance, and consider prescribing an emergency hydrocortisone injection kit. Sick day rules: double or triple oral corticosteroid dose for fever above 38.5°C or any significant illness; maintain until recovery. Vomiting or inability to take oral medications: inject 100 mg hydrocortisone IM and seek emergency care. Major surgery: continue usual corticosteroid dose and add stress-dose hydrocortisone 50 to 100 mg IV every 6 to 8 hours; taper rapidly over 24 to 48 hours postoperatively to basal dose. The key message for patients: never stop corticosteroids abruptly when taken for more than 3 weeks; carry the emergency card and injection at all times during the taper period.
Oakley RH, Cidlowski JA. The biology of the glucocorticoid receptor: new signaling mechanisms in health and disease. J Allergy Clin Immunol. 2013;132(5):1033-1044.
doi:10.1016/j.jaci.2013.09.007Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol. 2011;335(1):2-13.
doi:10.1016/j.mce.2010.04.005Barnes PJ. Corticosteroid effects on cell signalling. Eur Respir J. 2006;27(2):413-426.
doi:10.1183/09031936.06.00125404Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids — new mechanisms for old drugs. N Engl J Med. 2005;353(16):1711-1723.
doi:10.1056/NEJMra050541Franchimont D. Overview of the actions of glucocorticoids on the immune response: a good model to characterize new pathways of immunosuppression for new treatment targets. Ann N Y Acad Sci. 2004;1024:124-137.
doi:10.1196/annals.1321.009Liu D, Ahmet A, Ward L, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9(1):30.
doi:10.1186/1710-1492-9-30Nicolaides NC, Pavlaki AN, Maria Alexandra MA, Chrousos GP. Glucocorticoid therapy and adrenal suppression. In: Feingold KR, et al., eds. Endotext. MDText.com; 2018.
NBK279156Czock D, Keller F, Rasche FM, Häussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44(1):61-98.
doi:10.2165/00003088-200544010-00003Spies CM, Strehl C, van der Goes MC, Bijlsma JW, Buttgereit F. Glucocorticoids. Best Pract Res Clin Rheumatol. 2011;25(6):891-900.
doi:10.1016/j.berh.2011.11.002Derendorf H, Hochhaus G, Meibohm B, Möllmann H, Barth J. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. J Allergy Clin Immunol. 1998;101(4 Pt 2):S440-S446.
doi:10.1016/S0091-6749(98)70156-3Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. Updated 2023.
ginasthma.org/gina-reports/Dinsen S, Baslund B, Klose M, et al. Why glucocorticoid withdrawal may sometimes be as dangerous as the treatment itself. Eur J Intern Med. 2013;24(8):714-720.
doi:10.1016/j.ejim.2013.05.014Rushworth RL, Torpy DJ, Falhammar H. Adrenal crises: perspectives and research directions. Endocrine. 2017;55(2):336-345.
doi:10.1007/s12020-016-1204-2